Eric Genaro Salmerón

Dr. Eric Genaro Salmerón


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 December 2022 in Pathogens
Verified
Journal Article
Open access
PDF file
VHVíctor Daniel Priego Hernández
Víctor Daniel Priego Hernández
Adán Arizmendi-IzazagaAdán Arizmendi-Izazaga
Adán Arizmendi-Izazaga
DSDiana G. Soto-Flores
Diana G. Soto-Flores
NSNorma Santiago-Ramón
Norma Santiago-Ramón
MFMilagros D. Feria-Valadez
Milagros D. Feria-Valadez
Julio Ortiz-OrtizJulio Ortiz-Ortiz
Julio Ortiz-Ortiz
Cervical cancer (CC) is the most common cancer in women in the lower genital tract. The main risk factor for developing CC is persistent infection with HPV 16. The E6 and E7 oncoproteins of HPV 16 have been related to metabolic reprogramming in cancer through the regulation of the expression and stability of HIF-1α and consequently of the expression of its target genes, such as HIF1A (HIF-1α), SLC2A1 (GLUT1), LDHA, CA9 (CAIX), SLC16A3 (MCT4), and BSG (Basigin or CD147), which are involved in glucose metabolism. This work aimed to evaluate the expression of HIF-1α, GLUT1, LDHA, CAIX, MCT4, and Basigin in patient samples and CC cell lines. To evaluate the expression level of HIF1A, SLC2A1, LDHA, CA9, SLC16A3, and BSG genes in tissue from patients with CC and normal tissue, the TCGA dataset was used. To evaluate the expression level of these genes by RT-qPCR in CC cell lines, HPV-negative (C-33A) and HPV-16-positive (SiHa and Ca Ski) cell lines were used. Increased expression of HIF1A, SLC2A1, LDHA, SLC16A3, and BSG was found in Ca Ski and CA9 in SiHa compared to C-33A. Similar results were observed in CC tissues compared to normal tissue obtained by bioinformatics analysis. In conclusion, the expression of HIF-1α, GLUT1, LDHA, CAIX, MCT4, and BSG genes is increased in CC and HPV-16-positive cell lines.

Verified
Journal Article
Open access
PDF file
ESEric Genaro Salmerón
Eric Genaro Salmerón
AZAna Elvira Zacapala-Gómez
Ana Elvira Zacapala-Gómez
FTFrancisco I. Torres-Rojas
Francisco I. Torres-Rojas
VAVERÓNICA ANTONIO-VÉJAR
VERÓNICA ANTONIO-VÉJAR
PAPedro Avila
Pedro Avila
HJHilda Jiménez-Wences
Hilda Jiménez-Wences
Breast Cancer (BC) was the most common female cancer in incidence and mortality worldwide in 2020. Similarly, BC was the top female cancer in the USA in 2022. Risk factors include earlier age at menarche, oral contraceptive use, hormone replacement therapy, high body mass index, and mutations in BRCA1/2 genes, among others. BC is classified into Luminal A, Luminal B, HER2-like, and Basal-like subtypes. These BC subtypes present differences in gene expression signatures, which can impact clinical behavior, treatment response, aggressiveness, metastasis, and survival of patients. Therefore, it is necessary to understand the epigenetic molecular mechanism of transcriptional regulation in BC, such as DNA demethylation. Ten-Eleven Translocation (TET) enzymes catalyze the oxidation of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC) on DNA, which in turn inhibits or promotes the gene expression. Interestingly, the expression of TET enzymes as well as the levels of the 5hmC epigenetic mark are altered in several types of human cancers, including BC. Several studies have demonstrated that TET enzymes and 5hmC play a key role in the regulation of gene expression in BC, directly (dependent or independent of DNA de-methylation) or indirectly (via interaction with other proteins such as transcription factors). In this review, we describe our recent understanding of the regulatory and physiological function of the TET enzymes, as well as their potential role as biomarkers in BC biology.

Verified
Journal Article
Open access
PDF file
Adán Arizmendi-IzazagaAdán Arizmendi-Izazaga
Adán Arizmendi-Izazaga
Napoleón Navarro-TitoNapoleón Navarro-Tito
Napoleón Navarro-Tito
HJHilda Jiménez-Wences
Hilda Jiménez-Wences
AEAdilene Evaristo-Priego
Adilene Evaristo-Priego
VPVíctor Daniel Priego-Hernández
Víctor Daniel Priego-Hernández
Julio Ortiz-OrtizJulio Ortiz-Ortiz
Julio Ortiz-Ortiz
Human papillomavirus 16 (HPV 16) infection is associated with several types of cancer, such as head and neck, cervical, anal, and penile cancer. Its oncogenic potential is due to the ability of the E6 and E7 oncoproteins to promote alterations associated with cell transformation. HPV 16 E6 and E7 oncoproteins increase metabolic reprogramming, one of the hallmarks of cancer, by increasing the stability of hypoxia-induced factor 1 α (HIF-1α) and consequently increasing the expression levels of their target genes. In this report, by bioinformatic analysis, we show the possible effect of HPV 16 oncoproteins E6 and E7 on metabolic reprogramming in cancer through the E6-E7-PHD2-VHL-CUL2-ELOC-HIF-1α axis. We proposed that E6 and E7 interact with VHL, CUL2, and ELOC in forming the E3 ubiquitin ligase complex that ubiquitinates HIF-1α for degradation via the proteasome. Based on the information found in the databases, it is proposed that E6 interacts with VHL by blocking its interaction with HIF-1α. On the other hand, E7 interacts with CUL2 and ELOC, preventing their binding to VHL and RBX1, respectively. Consequently, HIF-1α is stabilized and binds with HIF-1β to form the active HIF1 complex that binds to hypoxia response elements (HREs), allowing the expression of genes related to energy metabolism. In addition, we suggest an effect of E6 and E7 at the level of PHD2, VHL, CUL2, and ELOC gene expression. Here, we propose some miRNAs targeting PHD2, VHL, CUL2, and ELOC mRNAs. The effect of E6 and E7 may be the non-hydroxylation and non-ubiquitination of HIF-1α, which may regulate metabolic processes involved in metabolic reprogramming in cancer upon stabilization, non-degradation, and translocation to the nucleus.

Verified
Journal Article
Open access
PDF file
LÁLissuly Guadalupe Álvarez-Hilario
Lissuly Guadalupe Álvarez-Hilario
ESEric Genaro Salmerón
Eric Genaro Salmerón
PAPedro Avila
Pedro Avila
GHGeorgina Hernández-Montes
Georgina Hernández-Montes
EAElena Arechaga-Ocampo
Elena Arechaga-Ocampo
RHRosaura Hernández-Rivas
Rosaura Hernández-Rivas
Among malignant neoplasms, pancreatic ductal adenocarcinoma (PDAC) has one of the highest fatality rates due to its late detection. Therefore, it is essential to discover a noninvasive, early, specific, and sensitive diagnostic method. MicroRNAs (miRNAs) are attractive biomarkers because they are accessible, highly specific, and sensitive. It is crucial to find miRNAs that could be used as possible biomarkers because PDAC is the eighth most common cause of cancer death in Mexico. With the help of microRNA microarrays, differentially expressed miRNAs (DEmiRNAs) were found in PDAC tissues. The presence of these DEmiRNAs in the plasma of Mexican patients with PDAC was determined using RT-qPCR. Receiver operating characteristic curve analysis was performed to determine the diagnostic capacity of these DEmiRNAs. Gene Expression Omnibus datasets (GEO) were employed to verify our results. The Prisma V8 statistical analysis program was used. Four DEmiRNAs in plasma from PDAC patients and microarray tissues were found. Serum samples from patients with PDAC were used to validate their overexpression in GEO databases. We discovered a new panel of the two miRNAs miR-222-3p and miR-221-3p that could be used to diagnose PDAC, and when miR-221-3p and miR-222-3p were overexpressed, survival rates decreased. Therefore, miR-222-3p and miR-221-3p might be employed as noninvasive indicators for the diagnosis and survival of PDAC in Mexican patients.

Verified
Journal Article
Open access
PDF file
ESEric Genaro Salmerón
Eric Genaro Salmerón
AZAndrea Martinez Zayas
Andrea Martinez Zayas
MVMiguel VARGAS
Miguel VARGAS
NVNicolás Villegas-Sepúlveda
Nicolás Villegas-Sepúlveda
PDPaola Briseño Diaz
Paola Briseño Diaz
RHRosaura Hernández-Rivas
Rosaura Hernández-Rivas
Genomic DNA methylation is an epigenetic modification that primarily occurs at CpG sites and is associated with the transcriptional repression of genes. This process plays a crucial role in maintaining cellular homeostasis and is catalyzed by a family of enzymes known as DNA methyltransferases (DNMTs), which includes DNMT1, DNMT2, DNMT3A, DNMT3B, and DNMT3L. DNMT1 is classified as a maintenance methyltransferase, whereas DNMT3A and DNMT3B are responsible for de novo methylation. Altered expression of DNMTs has been reported in various human diseases, including cancer. Cancer remains a major global health issue, with an estimated 20 million new cases and 9.7 million deaths reported in 2022. Among women, cervical cancer (CC) ranks fourth in both incidence and mortality worldwide, with persistent infection by high-risk human papillomavirus (HR-HPV) being the primary risk factor. Several studies have demonstrated that DNMT expression and activity are upregulated in CC, suggesting their potential as diagnostic and prognostic biomarkers. HR-HPV infection appears to increase DNMT expression, thereby promoting cervical carcinogenesis through aberrant methylation and subsequent silencing of tumor-suppressor genes such as PTEN, PAX1, and TSLC1. Furthermore, DNMTs are being explored as therapeutic targets in CC. In this review, we summarize the current state of the art regarding DNMTs in cervical cancer and discuss their functional roles and potential utility as diagnostic, prognostic, and therapeutic biomarkers.

1 February 2024
Verified
Journal Article
Closed access
AZA. E. Zacapala-Gomez
A. E. Zacapala-Gomez
MMM. A. Mendoza-Catalan
M. A. Mendoza-Catalan
VAV. Antonio-Vejar
V. Antonio-Vejar
HJH. Jimenez-Wences
H. Jimenez-Wences
JOJ. Ortiz-Ortiz
J. Ortiz-Ortiz
ESEric Genaro Salmerón
Eric Genaro Salmerón